Reich, Kristian, Eric L Simpson, Richard Langley, Richard B Warren, Antonio Costanzo, Hidehisa Saeki, Peter Almgren, Le Gjerum, Anna Carlsson, Melinda Gooderham, Andreas Pinter, Marjolein de Bruin-Weller, and Andrew Blauvelt. “Tralokinumab Demonstrated a Consistent Safety Profile With up to 42 Months of Treatment in Moderate-to-Severe Atopic Dermatitis: Including Adverse Events of Special Interest”. SKIN The Journal of Cutaneous Medicine 6, no. 6 (November 16, 2022): s79. Accessed September 20, 2024. https://dermsquared.com/skin/article/view/1837.